论文部分内容阅读
我院１９９３．２－１９９５．１０用骨膦治疗骨转移癌３２例，以评价骨膦在肿瘤骨转移综合治疗中的作用。其中肺癌１７例，乳腺癌１１例，鼻咽癌３例，肝癌１例。３２例经骨膦治疗后止痛总的有效率为８１．２５％，其中ＣＲ８例（２５％），ＰＲ１０例（３１．２５％），ＭＲ８例（２５％）。与治疗前相比，有明显疗效。有效患者的Ｋａｒｎｏｆｓｋｙ状况分级法分别提高２０－４０分，由于治疗后患者疼痛减轻，症状缓解，生存质量得到明显提高。我们认为骨膦联合放疗对控制广泛骨转移性骨痛，提高晚期肿瘤患者生存质量有实际意义。
In our hospital from 1993.2-1995.10, we used bone phosphine to treat 32 cases of bone metastases to evaluate the role of bone phosphine in the comprehensive treatment of tumor bone metastases. There were 17 cases of lung cancer, 11 cases of breast cancer, 3 cases of nasopharyngeal carcinoma, and 1 case of liver cancer. The total effective rate of analgesia in 32 cases treated with bony phosphine was 81.25%, including CR8 cases (25%), PR cases (31.25%), and MR cases (25%). Compared with before treatment, there is a clear effect. The Karnofsky status classification method for effective patients was increased by 20-40 points, respectively, due to the patient’s pain relief after treatment, the symptoms relieved, and the quality of life was significantly improved. We believe that bone phosphine combined with radiotherapy has practical significance for controlling extensive bone metastatic bone pain and improving the quality of life of advanced cancer patients.